Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A comparative study was carried out on two promising presynaptic dopamine transporter single-photon emission tomography (SPECT) radioligands with a fast pharmacokinetic profile, 123I-FP-β-CIT (FP) and 99mTc-TRODAT-1 (TR), in order to assess their differential diagnostic power in early parkinsonism and their sensitivity for detection of disease progression. This cross-sectional study was conducted on 96 patients with early-stage parkinsonism referred in a tertiary clinical setting. Mean disease duration was 2.0±1.3 years, and patients had a modified Hoehn and Yahr (H&Y) stage of 1–2 (average 1.2). Forty-seven patients received TR, and 49 received FP. In both groups, ten patients with normal presynaptic function were included as a control population; all other patients were clinically diagnosed as having idiopathic Parkinson’s disease. Groups were matched for gender, age, disease duration and modified H&Y stage. Triple-head gamma camera SPECT was analysed using a semiquantitative index of transporter binding (BI). Discriminant analysis with cross-validation resulted in a maximal classification accuracy for FP of 93% (sensitivity 95% and specificity 86%) for the contralateral putamen BI. For TR, the corresponding values were 87% accuracy, 92% sensitivity and 70% specificity. For FP, disease duration was correlated with both the putamen BI (−8.8%/year, ρ=−0.41, P=0.025) and the putamen/caudate ratio (−7.4%/year, ρ=−0.51, P=0.004), but for TR no significant correlation was found (all P values >0.5). In conclusion, both FP and TR show high sensitivity in a clinically relevant setting, but FP has superior accuracy for early differential diagnosis of idiopathic parkinsonism and non-degenerative extrapyramidal disorders, as well as better sensitivity for disease follow-up.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181–184.
- Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56:33–39.
- Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson’s disease. Ann Neurol 2003; 53 Suppl 3:S110–S118.
- Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology 2000; 55:1540–1547.
- Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26:171–182. CrossRef
- Kung HF, Kung MP, Choi SR. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med 2003; 33:2–13. CrossRef
- Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT Study Group. Mov Disord 2000; 15:503–510. CrossRef
- Pirker W, Asenbaum S, Bencsits G, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000; 15:1158–1167.
- Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 1993; 94:137–146.
- Tissingh G, Bergmans P, Winogrodzka A, et al. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1997; 38:1271–1272.
- Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson’s disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998; 29:128–141. CrossRef
- Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med 1998; 39:1500–1508.
- Kung HF. Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent. Nucl Med Biol 2001; 28:505–508. CrossRef
- Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson’s disease with99mTc-TRODAT-1 imaging. J Nucl Med 2001; 42:1303–1308.
- Johannsen B, Pietzsch HJ. Development of technetium-99m-based CNS receptor ligands: have there been any advances? Eur J Nucl Med Mol Imaging 2002; 29:263–275. CrossRef
- Maes A, Vanbilloen H, Cleynhens B, Mortelmans L, Bormans G, Verbruggen A.99mTc-M-TRODAT is not superior to 99mTc-TRODAT-1 for the diagnosis of Parkinson’s disease. Eur J Nucl Med Mol Imaging 2003; 30:796–797.
- Huang WS, Chiang YH, Lin JC, Chou YH, Cheng CY, Liu RS. Crossover Study of99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson’s disease patients. J Nucl Med 2003; 44:999–1005.
- Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427–442.
- Meegalla SK, Plossl K, Kung MP, et al. Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J Med Chem 1997; 40:9–17. CrossRef
- Cleynhens J, Vanbilloen H, Bormans G, de Groot T, Verbruggen A. Synthesis and isolation of the diastereomers of 4-tolyl,4-ethylphenyl- and 2,4-dimethylphenyl derivatives of99mTc-TRODAT-1. J Labelled Compd Radiopharm 2001; 44:S529–S531. CrossRef
- Kushner SA, McElgin WT, Kung MP, et al. Kinetic modeling of [99mTc]TRODAT-1: a dopamine transporter imaging agent. J Nucl Med 1999; 40:150–158.
- Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson’s disease by [123I]FPCIT SPECT. J Nucl Med 1999; 40:753–761.
- Kao PF, Tzen KY, Yen TC, et al. The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson’s disease. Nucl Med Commun 2001; 22:151–154. CrossRef
- Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28:266–272.
- Efron B. Estimating the error rate of a prediction rule: improvements on cross-validation. J Am Stat Assoc 1983; 78:316–331.
- Mozley PD, Schneider JS, Acton PD, et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson’s disease and in healthy volunteers. J Nucl Med 2000; 41:584–589.
- Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57:278–284.
- Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med 2003; 44:839–845.
- Van Laere K, Koole M, Versijpt J, et al. Transfer of normal99mTc-ECD brain SPET databases between different gamma cameras. Eur J Nucl Med 2001; 28:435–449.
- Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 2000; 57:369–372.
- Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson’s disease. J Neural Transm 2001; 108:1011–1019. CrossRef
- Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology 2001; 57:2089–2094.
- Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002; 17:45–53. CrossRef
- Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. [123I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003; 74:294–298. CrossRef
- Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000; 23:34–44. CrossRef
- Hardie RJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F] dopa PET. J Neurol Neurosurg Psychiatry 1999; 66:256.
- Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 1996; 119 (Pt 2):585–591.
- Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001; 16:608–615. CrossRef
- Reader TA, Ase AR, Huang N, Hebert C, van Gelder NM. Neuroleptics and dopamine transporters. Neurochem Res 1998; 23:73–80. CrossRef
- Grunder G, Vernaleken I, Muller MJ, et al. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 2003; 28:787–794. CrossRef
- Innis RB, Marek KL, Sheff K, et al. Effect of treatment withl-dopa/carbidopa or l-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord 1999; 14:436–442. CrossRef
- Van Laere K, Warwick J, Versijpt J, et al. Analysis of clinical SPECT data based on anatomical standardization and reference to normal data: a ROC-based comparison of visual, semiquantitative and voxel-based methods. J Nucl Med 2002; 43:458–469.
- Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1
European Journal of Nuclear Medicine and Molecular Imaging
Volume 31, Issue 8 , pp 1119-1127
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Idiopathic parkinsonism
- Parkinson’s disease
- Differential diagnosis
- Industry Sectors
- Author Affiliations
- 1. Division of Nuclear Medicine, Leuven University Hospital and K.U. Leuven, Herestraat 49, 3000, Leuven, Belgium
- 2. Department of Neurology, Leuven University Hospital and K.U. Leuven, Leuven, Belgium
- 3. Department of Radiopharmaceutical Chemistry, Leuven University Hospital and K.U. Leuven, Leuven, Belgium